Oesophageal cancer Cancer Malignant neoplasm of oesophagus
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female 2. Primary care: aged 50 and over 3. With repeat prescription for acid-suppressant medication or with referral to dyspepsia service for investigation of upper GI symptoms 4. During COVID 2WW and urgent referrals will also be considered provided dysphagia is not severe to the extent that they cannot swallow a tablet
Exclusion criteria
Exclusion criteria: 1. Primary care: recorded regular prescriptions of NSAIDs 2. Primary care/dyspepsia patients: recorded diagnosis of a current or previous oro-pharynx, oesophageal or gastro-oesophageal tumour, or recorded BE 3. Primary care: received prior surgical intervention to the oesophagus 4. Difficulty in swallowing due to a known cerebrovascular accident or neurological disorder 5. Recorded oesophageal varices, cirrhosis of the liver 6. Unable to temporarily discontinue anti-thrombotic medication prior to procedure (in line with manufacturer’s guidance) 7. Lacking capacity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility and practical implementation steps of introducing CytospongeTM - TFF3 as a triage test for endoscopy to identify Barrett’s oesophagus, early cancer and other oesophageal conditions, assessed by the uptake of the Cytosponge when offered by a GP | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Patient experience assessed using questionnaires after the Cytosponge procedure 2. Data to inform the development of an App collected using focus groups and interviews after the Cytosponge procedure 3. Barriers and facilitators among patients assessed using questionnaires and interviews after the Cytosponge procedure | — |
Countries
England, United Kingdom